Floris van Delft, PhD

Head of R&D at SynAffix/Lonza

Speaker

Floris van Delft graduated in organic chemistry from Leiden University (1996, with honors) in the Netherlands. After a post-doctoral stay at the Scripps Research Institute (San Diego, USA), he has held assistant/associate professorship positions at the University of Amsterdam and Radboud University Nijmegen, as well as a special professorship at Wageningen University in the Netherlands (2015–2020). During his academic career, his research was focused primarily on click chemistry, carbohydrate chemistry and protein conjugation technologies. In 2010, Floris was a co-founder of Synaffix, of which he became the full-time chief scientific officer (CSO) in 2014. He has been the driving force behind the invention of the proprietary technologies that form the basis of Synaffix’ best-in-class antibody-drug conjugates (ADCs) for targeted cancer therapy. Floris has (co)authored >150 peer-reviewed publications and is the (co)inventor of >30 patents.